ASCO GI 2021 | TAGS: trifluridine/tipiracil in metastatic gastric adenocarcinoma

Michele Ghidini, MD, PhD, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Milan, Italy, provides an overview of the TAGS study (NCT02500043), a randomized Phase III trial in which patients with metastatic gastric adenocarcinoma were treated with oral trifluridine/tipiracil plus best supportive care or placebo plus best supportive care. Trifluridine/tipiracil was found to significantly improve overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer; combination trifluridine/tipiracil could represent a new treatment approach in this population who represent a high unmet medical need. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).